Despite infecting virtually every child on earth before age two and remaining a leading killer of infants globally, RSV has long lived in the shadow of influenza and SARS-CoV-2 in public health discourse. A sweeping 2025 review in Medicinal Research Reviews consolidates what the field now knows — and crucially, where dangerous knowledge gaps persist — across virology, epidemiology, immune response, and therapeutic strategy.
The review systematically maps RSV's structural biology, including the fusion (F) protein conformational dynamics that have become the primary target for both monoclonal antibodies and next-generation vaccine candidates. It covers the dual pre- and post-fusion states of the F protein, innate and adaptive immune evasion mechanisms the virus deploys, and the epidemiological patterns that concentrate disease burden in winter months and in three particularly vulnerable populations: infants under six months, immunocompromised individuals, and adults over 65. The authors document the global case burden — tens of millions of lower respiratory tract infections annually — alongside the still-limited therapeutic armamentarium, noting that no broadly approved vaccine existed at the time of the underlying research, though recent monoclonal antibody approvals like nirsevimab represent a partial breakthrough.
The timing of this review matters. The RSV vaccine and prophylaxis landscape has shifted faster in the last three years than in the previous five decades, with maternal vaccines and extended-half-life monoclonal antibodies entering clinical use. A review that synthesizes pre-clinical biology with emerging clinical evidence serves as a critical reset point for clinicians and researchers. That said, this is a narrative overview rather than a meta-analysis, which limits its ability to generate pooled effect estimates or rank interventions rigorously. Its primary value is orienting readers to a rapidly evolving field rather than resolving clinical questions. For health-conscious adults, the most actionable implication is understanding RSV's outsized risk to older adults — a population whose vaccine options are now expanding but whose awareness remains lower than warranted.